 Home > Active Ingredient News > Antitumor Therapy > Brit J Cancer: Anticancer therapy linked to epigenomic changes in childhood cancer survivors

Brit J Cancer: Anticancer therapy linked to epigenomic changes in childhood cancer survivors

 Last Update: 2022-04-24
 Source: Internet
 Author: User

Tags

morgellons disease treatment

furfuryl alcohol cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Treatment of childhood cancer has improved significantly in recent years, with overall survival rates for childhood cancer exceeding 80% in high-income countries
.

As a result, the number of adult childhood cancer survivors (CCS) continues to increase, with approximately 1 in 750 young adults surviving in the UK

They are at increased risk for long-term adverse health outcomes

In a study published in the British Journal of Cancer, an authoritative journal in the field of oncology, researchers aimed to investigate the association between anticancer treatment and long-term DNA methylation changes, which may be responsible for adverse late-stage health effects in patients with CCS.
key drivers
.

We performed genome-wide DNA methylation assessments in paired samples (pre/post-treatment) from 32 childhood cancer patients using methylation EPIC arrays
.

In addition, the researchers measured methylation levels in 32 samples from different adult CCS (average 22 years after diagnosis) and compared them with cancer-free controls (n = 284)

Following treatment in children with cancer, the researchers found extensive DNA methylation changes, including 146 differentially methylated regions (DMRs) that were consistently altered in 32 post-treatment samples
.

Analysis of adult CCS found matched methylation changes at 107/146 of the DMRs, suggesting that the changes may be preserved long-term after treatment

Thus, these new methylation changes may serve as biomarkers for assessing the normal cytotoxicity of treatments and predicting long-term health outcomes in CCS patients
.

These new methylation changes could serve as biomarkers for assessing the normal cytotoxicity of treatments and predicting long-term health outcomes in CCS patients
.

Original source:

Original Source: Original Source:

Natassia Robinson.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.